Halozyme Therapeutics Inc. (HALO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Halozyme Therapeutics Inc. (HALO) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How HALO Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | 83.6% | 33.6% | $316.9M | $644.6M | 18% |
| FY 2024 | $1.02B | 84.3% | 54.3% | $444.1M | $468.4M | 24.8% |
| FY 2023 | $829.3M | 44% | 40.7% | $281.6M | $351.3M | 5.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring HALO)
- ✓Live walkthrough of HALO's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.
HALO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Halozyme Therapeutics Inc. (HALO)?
In FY 2025 (10-K), HALO converted $1.4B of revenue into a 83.6% gross margin, 33.6% operating margin, and $644.6M in free cash flow (46.2% FCF margin).